Appendixes
Appendix A1: Glossary of Acronyms Used
Tests
Acronym |
Definition |
EIA |
Enzyme immunoassay |
FISH |
Fluorescence in-situ hybridization |
ICC |
Immunocytochemistry |
ICMA |
Immunochemiluminometric assay |
IHC |
Immunohistochemistry |
IRMA |
Immunoradiometric assay |
MEIA |
Microparticle enzyme immunoassay |
PCR |
Polymerase chain reaction |
RIA |
Radioimmunoassay |
RT-PCR |
Reverse transcriptase polymerase chain reaction |
Diseases
Acronym |
Definition |
ALL |
Acute lymphocytic leukemia |
AML |
Acute myelogenous leukemia |
APL |
Acute promyelocytic leukemia |
CLL |
Chronic lymphocytic leukemia |
CML |
Chronic myelogenous leukemia |
CTCL |
Cutaneous T-cell lymphoma |
FAP |
Familial adenomatous polyposis |
HNPCC |
Hereditary non-polyposis colon cancer |
MM |
Multiple myeloma |
NHL |
Non-Hodgkin's lymphoma |
PNH |
Paroxysmal nocturnal hemoglobinuria |
Return to Contents
Appendix A2: Synopsis of Select Commercial Diagnostic Laboratories
(Information from company Web sites)
Quest Diagnostics (Teterboro, NJ) www.questdiagnostics.com
Quest Diagnostics is the nation's leading provider of diagnostic testing,
information, and services. The information we provide to health care practitioners
and consumers enables them to make better decisions and improve care. With
$4.7 billion in annual revenues, Quest Diagnostics offers the broadest access
to clinical testing services through its national network of 30-plus regional
laboratories, approximately 155 rapid response laboratories and almost 2,000
patient service centers. Quest Diagnostics is the leading provider of specialty
testing, including gene-based testing, and is the leader in routine medical
testing, drugs of abuse testing, and anatomic pathology testing. Through
partnerships with pharmaceutical, biotechnology and information technology
companies, Quest Diagnostics provides support to help speed the development
of health care insights and new therapeutics.
Laboratory Corporation of America®, LabCorp® (Burlington, NC) www.labcorp.com
LabCorp is a pioneer in genomic testing and the commercialization of new
diagnostic technologies. LabCorp is one of the world's largest clinical laboratories,
with annual revenues of $3.1 billion in 2004. Headquartered in Burlington,
North Carolina, LabCorp has more than 23,500 employees and offers more than
4,400 clinical tests ranging from routine blood analyses to the most sophisticated
molecular diagnostics. LabCorp tests more than 340,000 specimens daily for
over 220,000 clients nationwide.
Specialty Laboratories (Valencia, CA) www.specialtylabs.com
Specialty Laboratories is a leading hospital-focused clinical reference
laboratory that performs highly advanced, clinically useful testing services
for hospitals, laboratories and physician specialist communities nationwide.
With an extensive menu of clinical tests for the diagnosis and treatment-management
of disease, Specialty offers clients a single-source solution for their esoteric
testing needs. Specialty also supports its test offering with distinguished
R&D capabilities. Through internal research programs and technology partnerships,
Specialty develops new and enhanced clinical tests for reliable and cost-effective
patient assessment.
Return
to Contents
Appendix A3: Additional Companies and Web Sites
Company |
Web site URL |
Abbot |
http://www.abbottdiagnostics.com/ |
Adnagen |
http://www.adnagen.com/ |
Agendia |
http://www.agendia.com/ |
AMDL |
http://www.amdl.com/ |
Applied Imaging Corp |
http://www.aicorp.com/ |
AstraZeneca |
http://www.astrazeneca.com/ |
BioCurex |
http://www.biocurex.com/ |
Cangene Biotech |
http://www.cangene.com/ |
CeMines |
http://www.cemines.com/ |
ChondroGene |
http://www.chondrogene.com/ |
Ciphergen Biosystems |
http://www.ciphergen.com/ |
Corixa |
http://www.corixa.com/ |
Correlogic |
http://www.correlogic.com/ |
Cytogen |
http://www.cytogen.com/ |
DakoCytomation |
http://www.dako.com/ |
Diagene |
http://www.diagene.com/ |
DiagnoCure |
http://www.diagnocure.com/ |
Epigenomics |
http://www.epigenomics.com/ |
Exagen |
http://www.exagendiagnostics.com/ |
Fujirebio Diagnostics |
http://www.fdi.com/ |
GenoID |
http://genoid.net/eng/welcome.html |
Genomic Health |
http://www.genomichealth.com/ |
Gen-Probe |
http://www.gen-probe.com/ |
Genzyme |
http://www.genzyme.com/ |
GMP Companies |
http://www.gmpcompanies.com/ |
Health Discovery Corporation |
http://www.healthdiscoverycorp.com/ |
Healthtronics |
http://www.healthtronics.com/ |
IMI Medical |
http://www.imimedical.com/ |
Immunicon |
http://www.immunicon.com/ |
Intergenetics |
http://www.intergenetics.com/ |
LabCorp |
http://www.labcorp.com/ |
Matritech Inc. |
http://www.matritech.com/ |
Medicorp |
http://www.medicorp.com/ |
Metagenex |
http://www.metagenex.fr/ |
Methexis |
http://www.methexis-genomics.com/ |
Microprevention Tests |
no Web site found |
Myriad Genetics |
http://www.myriad.com/ |
Orion Genomics |
http://www.oriongenomics.com/ |
Power3 |
http://www.power3medical.com/ |
Procyon |
http://www.procyonbiopharma.com/ |
Qualigen |
http://www.qualigeninc.com/ |
Quest Diagnostics |
http://www.questdiagnostics.com/ |
Roche |
http://www.roche-diagnostics.com/ |
Sequenom |
http://www.sequenom.com/ |
Specialty Laboratories |
http://www.specialtylabs.com/ |
Tessera |
http://www.tesserainc.com/ |
Tm Bioscience |
http://www.tmbioscience.com/ |
Tripath Imaging |
http://www.tripathimaging.com/ |
US LABS |
http://www.uslabs.net/ |
Veridex |
http://www.veridex.com/ |
ViroLogic |
http://www.monogrambio.com/ |
Vitatex |
http://www.vitatex.com/ |
Wako |
http://www.wakousa.com/ |
Return to Contents
Appendix A4: Exploratory MEDLINE Search Strategy: Genetic Tests for 10 Cancers
Ovid MEDLINE(R) 1966 to June Week 5 2005
# |
Search History |
Results |
1 |
exp "sensitivity and specificity" |
182609 |
2 |
exp Predictive Value of Tests/ |
61018 |
3 |
exp ROC CURVE/ |
7998 |
4 |
exp Mass Screening/ |
69062 |
5 |
exp diagnosis/ |
3543147 |
6 |
exp REPRODUCIBILITY OF RESULTS/ |
106784 |
7 |
exp false negative reactions/ or false positive reactions/ |
24280 |
8 |
predictive value.tw. |
26661 |
9 |
(sensitivity or specificity).tw. |
386606 |
10 |
accuracy.tw. |
90063 |
11 |
screening.tw. |
150990 |
12 |
roc.tw. |
5785 |
13 |
reproducibility.tw. |
23848 |
14 |
(false positive or false negative).tw. |
27567 |
15 |
likelihood ratio.tw. |
2116 |
16 |
or/1-15 |
3980953 |
17 |
exp genetic screening/ |
12094 |
18 |
((gene or genes or genetic$) and (diagno$ or test$ or screen$)).tw. |
169073 |
19 |
or/17-18 |
174880 |
20 |
exp cell culture techniques/ |
11135 |
21 |
exp cell line/ |
355216 |
22 |
In Vitro/ |
330724 |
23 |
exp biological assay/ |
24262 |
24 |
exp tumor stem cell assay |
3161 |
25 |
or/20-24 |
707287 |
26 |
(16 and 19) not 25 |
70418 |
27 |
limit 26 to humans |
16623 |
28 |
26 not 27 |
53795 |
29 |
limit 28 to english language |
48399 |
30 |
limit 29 to (addresses or bibliography or biography or case reports or congresses
or consensus development conference or consensus development conference, nih or
dictionary or directory or editorial or festschrift or government publications or
guideline or interview or lectures or legal cases or legislation or letter or meta
analysis or news or newspaper article or patient education handout or periodical
index or practice guideline or "review" or review, academic or "review literature"
or review, multicase or "review of reported cases" or review, tutorial) |
12504 |
31 |
29 not 30 |
35895 |
32 |
exp prostate neoplasms/ |
46076 |
33 |
31 and 32 |
352 |
34 |
limit 33 to yr=" 2000-2005" |
255 |
35 |
exp ovarian neoplasms/ |
39000 |
36 |
31 and 35 |
573 |
37 |
limit 36 to yr=" 2000-2005" |
354 |
38 |
exp colonic neoplasms/ |
45633 |
39 |
31 and 38 |
361 |
40 |
limit 39 to yr=" 2000-2005" |
164 |
41 |
exp lung neoplasms/ |
101151 |
42 |
31 and 41 |
428 |
43 |
limit 42 to yr=" 2000-2005 |
258 |
44 |
exp leukemia/ |
141459 |
45 |
31 and 44 |
922 |
46 |
limit 45 to yr=" 2000-2005 |
400 |
47 |
exp lymphoma, non-hodgkin/ |
53794 |
48 |
31 and 47 |
491 |
49 |
limit 48 to yr=" 2000-2005" |
256 |
50 |
exp breast neoplasms/ |
122806 |
51 |
31 and 50 |
1501 |
52 |
limit 51 to yr=" 2000-2005" |
902 |
53 |
exp esophageal neoplasms/ |
22840 |
54 |
31 and 32 |
88 |
55 |
limit 33 to yr="2000 - 2005" |
52 |
56 |
exp liver neoplasms/ |
79138 |
57 |
31 and 35 |
210 |
58 |
limit 36 to yr="2000 - 2005" |
123 |
59 |
exp pancreatic neoplasms/ |
31833 |
60 |
31 and 38 |
171 |
61 |
limit 39 to yr="2000 - 2005" |
110 |
62 |
33 or 36 or 39 or 42 or 45 or 48 or 51 or 54 or 57 or 60 |
4492 |
63 |
34 or 37 or 40 or 43 or 46 or 49 or 52 or 55 or 58 or 61 |
2519 |
Return to Contents
Appendix A5: Sample Titles from Searches of the Gray Literature Databases
a. LexisNexis
"Collaboration to focus on the role of DNA in colon cancer detection"
"Tm Bioscience to manufacture novel breast cancer risk testing reagents
for Intergenetics"
"Matritech says study data show its bladder-cancer test is cost-effective"
b. Cambridge Healthtech Institute (CHI)
"Abbott Data Published in Nature Reveals A Promising New Approach
to Cancer"
"ACADIA Pharmaceuticals Expands Technology Platform to Target Tyrosine
Kinase Linked Receptors"
"Broad Institute to Conduct Large-Scale Genotyping Project Using
Affymetrix Technology."
c. Computer Retrieval of Information on Scientific Projects (CRISP)
"Genetic Abnormalities Early on the Path of Breast Cancer"
"CYP1A1 and CYP1B1 genes in race-related Prostate Cancer"
"LEF/TCF Expression in Colon Cancer"
d. Web of Knowledge
"Induction of Th1-type immunity and tumor protection with a prostate-specific
antigen DNA vaccine"
"Pituitary tumor transforming gene (PTTG) induces genetic instability
in thyroid cells"
"Novel mechanism of inhibition of nuclear factor-kappa B DNA-binding
activity by diterpenoids isolated from Isodon rubescens"
e. Early Detection Research Network (EDRN)
f. National Research Register (NRR)
"Analysis of BRCA1 gene mutations in familial and early onset breast
cancer"
"An investigation of susceptibility genes for prostate cancer"
"Analysis of expression of RNA profiles in primary breast cancer"
g. Canadian Institute of Scientific and Technical Information (CISTI)
"Detection of Metastatic Potential in Breast Cancer by Rho-GTPase
and WISP3 Proteins"
"Identification of HP1 Target Genes Involved in Progression of Breast
Cancer"
"Investigation of Alpha6 Integrins and Their Signaling Intermediates
as Prognostic Markers for Breast Cancer"
h. Google
"New Test Predicts Breast Cancer Risk"
"New Gene Chip may be Cancer Diagnostic Tool"
"Silenced Gene Suggests Greater Risk, Possible Marker For African-Americans
With Prostate Cancer"
i. Clinical Laboratory Improvement Amendments (CLIA)
"Abbott Architect I2000 system (Fujirebio Diagnostics Inc, Architect
CA 15-3 reagent kit)"
"Asymmetrx prostate-63 cancer diagnostic reagent"
"TOSOH AIA-360 (ST AIA Pack 27.29)"
j. The Office of In Vitro Diagnostics Device Evaluation and Safety (OIVD)
"Dakocytomation HER2 FISH PharmDx Kit"
"Urovysion bladder cancer kit"
"Architect CA 15-3 assay"
k. FDA Pre-market Approval
"immunochemistry analyzer"
"prostate specific antigen (PSA) for detection and management of
prostate cancers"
"digital mammographic x-ray system"
l. ClinicalTrials.gov
"Microarray Analysis for Human Genetic Disease"
"Genetic and Environmental Risk Assessment for Colorectal Cancer
in Healthy Participants"
"Microsatellite Analysis of Urinary Sediment in Detecting Bladder
Cancer"
m. Online Computer Library Center (OCLC)’s FirstSearch
"Novel Pentablock Copolymers as Non-Viral Vectors for Gene Therapy
against Cancer"
"451-034: Fuzzy Neural Network Applications for Gene Selection and
Cancer Classification"
"APC, K-ras, and p53 Gene Mutations in Colorectal Cancer Patients:
Correlation to Clinicopathologic Features and Postoperative Surveillance"
n. Health Technology Assessment Database (HTA)
"Screening for ovarian cancer: a systematic review"
"Genetic diagnosis by PCR," and
"Colorectal cancer screening."
o. NY Academy of Medicine
"Community health profiles: the health of Southwest Brooklyn"
"FDA hinders cancer vaccines"
"Fulfilling the potential of cancer prevention and early detection:
an American Cancer Society and Institute of Medicine Symposium"
p. GrayLIT Network
"Cancer risk assessment: Should new science be applied? A workgroup
summary"
"Targeting human breast cancer cells that overexpress HER-2/neu mRNA
by an antisense iron responsive element"
"Investigation of the candidate tumor suppressor gene PRK in prostate
cancer"
q. Health Services Research Projects in Progress (HSRProj)
"Improving palliative care in chronic critical illness"
"Mammography disparities in elderly African American women"
"Socio-ecological variables/cancer screening behaviors"
Return to Contents
Prepared for AHRQ under Contract No. 290-02-0022. By Kevin M. Chin,
M.D., M.S., Benjamin Wessler, B.A., Priscilla Chew, M.P.H., and Joseph
Lau, M.D.; Tufts-New England Medical Center Evidence-based Practice Center.
Current as of January 2006
Internet Citation:
Genetic Tests for Cancer. Technology Assessment. January
2006. Rockville, MD: Agency for Healthcare Research and Quality. http://www.ahrq.gov/clinic/ta/gentests/